Blog
RSS FeedPosted by Michael Wonder on 30 Jun 2023
Endo announces approval of Xcopri (cenobamate tablets) in Canada
29 June 2023 - Endo International announced today that Paladin Labs, an Endo operating company, received Health Canada's approval of ...
Posted by Michael Wonder on 29 Jun 2023
Ontario to publicly reimburse Albrioza for the treatment of ALS
28 June 2023 - Ontario lists Albrioza on its drug benefit formulary, becoming the first province to publicly reimburse Albrioza, ...
Posted by Michael Wonder on 27 Jun 2023
Sun Pharma announces Health Canada approval of Absorica LD (isotretinoin capsules) for treatment of severe nodular acne
26 June 2023 - A new formulation of isotretinoin, the first in over a decade and the only micronised formulation ...
Posted by Michael Wonder on 21 Jun 2023
Imbruvica is included in the high-cost protection with a changed benefit limitation
19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...
Posted by Michael Wonder on 20 Jun 2023
FDA launches pilot program to help reduce risks associated with using laboratory developed tests to identify cancer biomarkers
20 June 2023 - Pilot geared toward sponsors of certain oncology drug products used with certainin vitro diagnostic tests ...
Posted by Michael Wonder on 20 Jun 2023
Sun Pharma announces Health Canada approval of Winlevi (clascoterone cream 1%) for topical treatment of acne
19 June 2023 - Winlevi is the first and only topical androgen receptor inhibitor, and the newest Health Canada-approved formulation to ...
Posted by Michael Wonder on 15 Jun 2023
Amylyx Pharmaceuticals completes negotiation process and signs letter of intent with the pCPA for Albrioza for the treatment of ALS
15 June 2023 - Amylyx will now work with federal, provincial, and territorial drug plans to ensure public coverage is available ...
Posted by Michael Wonder on 15 Jun 2023
Health Canada authorises Akeega (niraparib and abiraterone acetate) dual action tablets for targeted treatment of patients with metastatic castration-resistant prostate cancer with BRCA (1/2) gene mutations
14 June 2023 - Approval for Akeega is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision ...
Posted by Michael Wonder on 13 Jun 2023
Pilot expert committee to support decision-making across the drug life cycle
8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...
Posted by Michael Wonder on 12 Jun 2023
Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review
12 June 2023 - One-third of the new active substances approved in the United States and Europe between 2016 and ...
Posted by Michael Wonder on 08 Jun 2023
SAR443579/IPH6101 receives FDA fast track designation in the US for the treatment of haematological malignancies
8 June 2023 - SAR443579, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research ...
Posted by Michael Wonder on 05 Jun 2023
Upcoming improvements to the CADTH reimbursement review process
5 June 2023 - Today, CADTH is communicating a series of improvements that will further our ambition to innovate in ...
Posted by Michael Wonder on 05 Jun 2023
Guidance for reporting real world evidence
31 May 2023 - CADTH has partnered with Health Canada, the Institut national d’excellence en santé et en services sociaux (INESSS), ...
Posted by Michael Wonder on 31 May 2023
Brukinsa approved in Canada for the treatment of chronic lymphocytic leukaemia
30 May 2023 - BeiGene’s Bruton's tyrosine kinase inhibitor is approved in more than 65 markets globally. ...
Posted by Michael Wonder on 30 May 2023
Valneva files for Chikungunya vaccine authorisation with Health Canada
30 May 2023 - Valneva today announces the filing of a regulatory application with Health Canada for marketing approval of ...